Next-generation cancer vaccine approaches: Integrating lessons learned from current successes with promising biotechnologic advances

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 7, 2013, Pages 766-772

  Le, Dung T ^a   Jaffee, Elizabeth M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; CANCER VACCINE; CAPECITABINE; CRS 207; CYCLOPHOSPHAMIDE; DNA VACCINE; DOCETAXEL; EMEPEPIMUT S; FLUTAMIDE; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; GSK 2132231A; IMA 901; IPILIMUMAB; KEYHOLE LIMPET HEMOCYANIN; LOVAXIN C; NELIPEPIMUT S; PIDILIZUMAB; PLACEBO; POL 103A; PROSTATAK; RILIMOGENE GALVACIREPVEC; RINDOPEPIMUT; SIPULEUCEL T; SUNITINIB; TEMOZOLOMIDE; TERTOMOTIDE; THYMIDINE KINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BIOTECHNOLOGICAL PRODUCTION; BIOTECHNOLOGY; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL; DRUG APPROVAL; DRUG INDICATION; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; METASTATIC MELANOMA; NEOPLASM; PANCREAS ADENOCARCINOMA; PROSTATE CANCER; T LYMPHOCYTE; VACCINE PRODUCTION;

EID: 84882984973     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0099     Document Type: Article

References (33)

1. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-422.
2. Frohlich MW. Sipuleucel-T for the treatment of advanced prostate cancer. Semin Oncol 2012;39:245-252.
3. Lubaroff DM. Prostate cancer vaccines in clinical trials. Expert Rev Vaccines 2012;11:857-868.
4. Drake CG, Antonarakis ES. Current status of immunological approaches for the treatment of prostate cancer. Curr Opin Urol 2012;22:197-202.
5. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010;11:155-164.
6. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723.
7. Singh N, Madan RA, Gulley JL. Ipilimumab in prostate cancer. Expert Opin Biol Ther 2013;13:303-313.
8. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-3175.
9. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti- PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-2465.
10. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-2454.
11. Schuster SJ, Neelapu SS, Gause BL, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 2011;29:2787-2794.
12. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011;364:2119-2127.
13. Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 2012;104:599-613.
14. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-7420.
15. Stein WD, Gulley JL, Schlom J, et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 2011;17:907-917.
16. Sanda MG, Smith DC, Charles LG, et al. Recombinant vaccinia- PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology 1999;53:260-266.
17. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:1099-1105.
18. Gulley JL, Arlen PM, Madan RA, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 2010;59:663-674.
19. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003;21:1232-1237.
20. Higano C, Saad F, Somer B, et al. A Phase III trial GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer [abstract]. Presented at the 2009 Genitourinary Cancers Symposium; February 26-28, 2009; Orlando, Florida. Abstract LBA150 2009.
21. Small E, Demkow T, Gerritsen WR, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer [abstract]. Presented at the 2009 Genitourinary Cancers Symposium; February 26-28, 2009; Orlando, Florida. Abstract 7.
22. Le DT, Pardoll DM, Jaffee EM. Cellular vaccine approaches. Cancer J 2010;16:304-310.
23. Le DT, Brockstedt DG, Nir-Paz R, et al. A live-attenuated listeria vaccine (ANZ-100) and a live-attenuated listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res 2012;18:858-868.
24. Radulovic S, Brankovic-Magic M, Malisic E, et al. Therapeutic cancer vaccines in cervical cancer: phase I study of Lovaxin-C. J BUON 2009;14(Suppl 1):S165-168.
25. Zheng L, Foley K, Huang L, et al. Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer. PLoS One 2011;6:e19390.
26. van den Eertwegh AJ, Versluis J, van den Berg HP, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012;13:509-517.
27. Hsu DK, Chen HY, Liu FT. Galectin-3 regulates T-cell functions. Immunol Rev 2009;230:114-127.
28. Mhawech-Fauceglia P, Zhang S, Terracciano L, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology 2007;50:472-483.
29. Madan RA, Mohebtash M, Arlen PM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012;13:501-508.
30. Le DT, Lutz E, Uram JN, et al. Evaluation of Ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunol, in press.
31. Segal NH, Parsons DW, Peggs KS, et al. Epitope landscape in breast and colorectal cancer. Cancer Res 2008;68:889-892.
32. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-1806.
33. Castle JC, Kreiter S, Diekmann J, et al. Exploiting the mutanome for tumor vaccination. Cancer Res 2012;72:1081-1091.